JP4170419B2 - Heteromonocyclic carboxylic ester-based novel substance and hair nourishing composition containing novel substance - Google Patents
Heteromonocyclic carboxylic ester-based novel substance and hair nourishing composition containing novel substance Download PDFInfo
- Publication number
- JP4170419B2 JP4170419B2 JP20244997A JP20244997A JP4170419B2 JP 4170419 B2 JP4170419 B2 JP 4170419B2 JP 20244997 A JP20244997 A JP 20244997A JP 20244997 A JP20244997 A JP 20244997A JP 4170419 B2 JP4170419 B2 JP 4170419B2
- Authority
- JP
- Japan
- Prior art keywords
- novel substance
- hair
- pentadecyl
- substance
- chart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000126 substance Substances 0.000 title claims description 57
- 239000000203 mixture Substances 0.000 title claims description 16
- -1 Heteromonocyclic carboxylic ester Chemical class 0.000 title description 21
- UCZLSNQPQXBXSK-UHFFFAOYSA-N pentadecyl furan-2-carboxylate Chemical compound CCCCCCCCCCCCCCCOC(=O)C1=CC=CO1 UCZLSNQPQXBXSK-UHFFFAOYSA-N 0.000 claims description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 24
- 230000003779 hair growth Effects 0.000 description 19
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 238000000862 absorption spectrum Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000004817 gas chromatography Methods 0.000 description 9
- NFPSLIQTFRKCSR-UHFFFAOYSA-N C(CCCCCCCCCCCCCC)OC(=O)C1OCCC1 Chemical compound C(CCCCCCCCCCCCCC)OC(=O)C1OCCC1 NFPSLIQTFRKCSR-UHFFFAOYSA-N 0.000 description 8
- OTTMOGZXUVEVQZ-UHFFFAOYSA-N pentadecyl thiophene-2-carboxylate Chemical compound CCCCCCCCCCCCCCCOC(=O)C1=CC=CS1 OTTMOGZXUVEVQZ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 239000010779 crude oil Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- UJJLJRQIPMGXEZ-UHFFFAOYSA-N tetrahydro-2-furoic acid Chemical compound OC(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-N 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UTVVREMVDJTZAC-UHFFFAOYSA-N Nc1ccc[o]1 Chemical compound Nc1ccc[o]1 UTVVREMVDJTZAC-UHFFFAOYSA-N 0.000 description 1
- 241000183666 Nepsera aquatica Species 0.000 description 1
- 239000009724 Salvia extract Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229940105017 achillea millefolium extract Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- AAFIBPAFMTWDBF-UHFFFAOYSA-N butane-1,3-diol;ethanol Chemical compound CCO.CC(O)CCO AAFIBPAFMTWDBF-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- DDAXSEWWNPAMQN-UHFFFAOYSA-N pentadecyl pyridine-3-carboxylate Chemical compound CCCCCCCCCCCCCCCOC(=O)C1=CC=CN=C1 DDAXSEWWNPAMQN-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Cosmetics (AREA)
Description
【0001】
【発明の属する技術分野】
この発明は、複素単環カルボン酸エステル系新規物質群及びこれら新規物質並びにその類似物質を含有する養毛剤組成物に係り、その目的は、優れた育毛作用を有する新規物質及びこれら新規物質或いはその類似物質を配合した優れた育毛効果を奏する育毛剤組成物を提供することにある。
尚、この発明に係る育毛剤組成物は、薬事法上の医薬品、医薬部外品、化粧品等のいずれに属していてもよい。
【0002】
【従来の技術】
従来より、養毛剤としては特開平1−250310号公報:発明の名称「育毛剤」に記載されたものが開示されている。
しかしながら、特開平1−250310号公報に開示されたn−ペンタデカノールのニコチン酸エステルは育毛作用が充分ではなく、これらを有効成分とする養毛剤は実用化するほどの効力はなかった。
そこで、さらに優れた育毛作用を有する化合物及び育毛効果に優れた育毛剤組成物の創出が望まれていた。
【0003】
【発明が解決しようとする課題】
上記事情に鑑み、この発明においては、優れた育毛作用を有する新規物質及びこれらの新規物質を含有し、優れた育毛効果を奏する養毛剤組成物を提供することを目的とする。
【0004】
【課題を解決するための手段】
請求項1に記載の発明は、下式(化2)で示される新規物質n−Pentadecyl−2−furoateである。
【化 2】
請求項2に記載の発明は、新規物質n−Pentadecyl−2−furoateが配合されてなる育毛剤組成物である。請求項3に記載の発明は、新規物質n−Pentadecyl−2−furoateを0.01〜10重量%配合してなる育毛剤組成物である。これらの発明を提供することにより、上記の課題を悉く解決する。なお、これまでに複素環のヘテロ原子が窒素であるカルボン酸エステルの育毛作用は知られているが、ヘテロ原子が酸素であるカルボン酸エステルに育毛作用が認められたのは始めてである。
【0005】
【発明の実施の形態】
以下、この発明の実施の形態を詳細に説明する。
請求項1に記載の複素単環カルボン酸エステル系新規物質は次式(化3)で表されるn−Pentadecyl−2−furoateである。
【化 3】
n−Pentadecyl−2−furoateは分子量が322、融点が36〜37℃、常温では褐色の結晶である。
【0006】
以下、この発明の複素単環カルボン酸エステル系新規物質の合成方法について説明する。この発明の新規物質はn−ペンタデカノール(化4)と複素単環カルボン酸2−furoic acid(化5)、2−thenoic acid(化6)、tetrahydro−2−furoic acid(化7)とをエステル化させることによって合成される。
【化4】
【化5】
【化6】
【化7】
エステル化の方法は常法に従えばよく特に限定されないが、n−ペンタデカノールと複素単環カルボン酸の両方を溶解させることができる溶媒にこれらn−ペンタデカノールと複素単環カルボン酸を溶解させ、触媒を添加して所定の温度に加熱して縮合する方法が例示できる。
【0008】
以下、この発明で使用する新規物質である複素単環カルボン酸エステル系化合物の合成方法について説明する。この発明で使用する複素単環カルボン酸エステル系化合物はn−ペンタデカノール(化8)と複素単環カルボン酸(化9)とをエステル化させることによって合成される。
【化8】
【化9】
なお、化9は、2−furoic acid(化10)が好適に使用される。
【化10】
【0009】
上記の方法により合成された、新規物質n−Pentadecyl−2−furoateは育毛作用を有するため、有効成分として配合すると、好適な養毛剤が得られる。この場合、配合量は0.01〜10%程度であると好ましい。配合量が0.01%未満であると育毛効果が得られない場合があり、10%を越えて配合しても育毛効果の大幅な向上は望めないからである。この発明の養毛剤には上記有効成分の他に血行促進剤、局所刺激剤等を配合してもよく、具体的にはビタミンE及びその誘導体、センブリエキス、ニンニクエキス、セファランチン、塩化カルプロニウム、アセチルコリン等の血行促進剤、トウガラシチンキ、カンタリスチンキ、ショウキョウチンキ、ノニル酸バニルアミド等の局所刺激剤、サリチル酸、レゾルシン、乳酸などの角質溶解剤、プラセンタエキス、ペンタデカン酸グリセリド、パントテニルエチルエーテル、ビオチン、ヒノキチオール、アラントイン等の代謝賦活剤、グリチルリチン酸、グリチルレチン酸等の消炎剤、イソプロピルメチルフェノール、トリクロサン、ジンクピリチオン、ヒノキチオール等の殺菌剤、メントール、カンフル等の清涼剤、その他女性ホルモン等を適宜組み合わせて配合できる。また、この発明では前記した以外に、この発明の効果や系を損なわない範囲で、通常の他の成分、すなわちアルコ−ル、多価アルコール、水溶性高分子、酸化防止剤、pH調整剤、紫外線防止剤、金属イオン封鎖剤、増粘剤、界面活性剤、精製水、香料、防腐剤、抗菌剤、油剤、高級脂肪酸、脂肪酸エステル、保湿剤、清涼剤、色素等の通常の化粧品成分、或いはホルモン類、ビタミン類、アミノ酸類、収れん剤及び胎盤抽出物、エラスチン、コラーゲン、ムコ多糖、アロエ抽出物、ヘチマ水、ローヤルゼリー、バーチ、ニンジンエキス、カモミラエキス、甘草エキス、サルビアエキス、アルテアエキス、セイヨウノコギリソウエキス等の生薬成分をはじめとする動植物抽出成分等特殊配合成分を、目的に応じて適宜任意に配合してもよい。
【0010】
【実施例】
以下、この発明の複素単環カルボン酸エステル系新規物質の合成方法について合成例1乃至3に基づいて説明する。
【0011】
〈合成例1〉
n−Pentadecyl−2−furoateの合成。
300mlフラスコ中にH管を付け、この中に2−furoic acid17.9g(0.16mol)、n−Pentadecanol 30.0g(0.13mol)、トシルアルコール1水和物 1g、及びトルエン200mlを仕込んだ。この溶液を115℃で5時間共沸させ、水分を除去した。なお、この時点での留出水量は約1.0mlであった。
その後溶液にトシルアルコール1水和物を2g加え、さらに8時間共沸させ、水分を除去した。なお、この時点での総留出水量は約2.3mlであった。
共沸後、この溶液を冷却し、飽和炭酸ナトリウム水溶液200ml内に注入してから、この中からトルエン層を取り出した。
取り出したトルエン層を飽和炭酸ナトリウム水溶液200mlで一回洗い、さらに地下カン水200mlで一回洗った後、トルエンを蒸発させて濃縮して原油42.0gを得た。この原油を95%エタノール80mlで再結晶させ、融点36〜37℃の褐色結晶物36.0gを得た。なお収率は86%であった。
得られた物質の同定は 1H核磁気共鳴スペクトル、13C核磁気共鳴スペクトル、質量分析、赤外線吸収スペクトル、ガスクロマトグラフィーによって行った。 1H核磁気共鳴スペクトル〔(CDCl3 )δH ppm〕は、溶媒としてCDCl3 を、基準物質としてTMS(27℃)を用い、サンプル1%濃度で行ったところ、0.88(3H,t,−CH3),1.26(24H,−(CH2)12−),1.70(2H,m,−COO−CH2−CH 2−),4.30(2H,t,−COO−CH2−),6.49(1H,dd,−CH−4),7.16(1H,dd,−CH−3),7.57(1H,dd,−CH−5)であった。
13C核磁気共鳴スペクトル〔(CDCl3 )δC ppm〕は、溶媒としてCDCl3 を、基準物質としてTMS(27℃)を用い、サンプル3%濃度で行ったところ、14.2(q),22.8(t),26.0(t),28.8(t),29.3(t),29.4(t),29.4(t×7),32.0(t),65.1(t),111.8(d),117.7(d),145.0(s),146.2(d),158.9(s)であった。
質量分析〔EIMS(%)〕の結果は、322(M+ ,38),277(4),210(14),113(100),95(42)であった。
赤外線吸収スペクトル〔IRνmax(KBr)cm-1〕の結果は、3100,2920,2850,1720,1705,1580,1475,1300,1130,1020,770であった。
なお、得られた物質の 1H核磁気共鳴スペクトルのチャートを図1に、13C核磁気共鳴スペクトルのチャートを図2に、質量分析結果のチャートを図3に、赤外線吸収スペクトルのチャートを図4に、ガスクロマトグラフィーのチャートを図5に示す。
【0012】
〈合成例2〉
n−Pentadecyl−2−thenoateの合成。
300mlフラスコ中にH管を付け、この中に2−Thenoic acid20.5g(0.16mol)、n−Pentadecanol 30.0g(0.13mol)、トシルアルコール1水和物 1g、及びトルエン200mlを仕込んだ。この溶液を115℃で5時間共沸させ、水分を除去した。なお、この時点での留出水量は約1.0mlであった。
その後溶液にトシルアルコール1水和物を2g加え、さらに8時間共沸させ、水分を除去した。なお、この時点での総留出水量は約2.2mlであった。
共沸後、この溶液を冷却し、飽和炭酸ナトリウム水溶液200ml内に注入してから、この中からトルエン層を取り出した。
取り出したトルエン層を飽和炭酸ナトリウム水溶液200mlで一回洗い、さらに地下カン水200mlで一回洗った後、トルエンを蒸発させて濃縮して原油50.0gを得、これをさらに蒸留塔にて蒸留した。
蒸留条件及び収量を表1に示す。
【表 1】
表1に記載の通り、n−Pentadecyl−2−thenoate(分画2)の収量は41.0gであり、収率は93%であった。
得られた物質の同定は 1H核磁気共鳴スペクトル、13C核磁気共鳴スペクトル、質量分析、赤外線吸収スペクトル、ガスクロマトグラフィーによって行った。
1H核磁気共鳴スペクトル〔(CDCl3 )δH ppm〕は、溶媒としてCDCl3 を、基準物質としてTMS(27℃)を用い、サンプル1%濃度で行ったところ、0.88(3H,t,−CH3),1.26(24H,−(CH2)12−),1.73(2H,m,−COO−CH2−CH 2 −),4.28(2H,t,−COO−CH2−),7.07(1H,dd,−CH−4),7.52(1H,dd,−CH−3),7.78(1H,dd,−CH−5)であった。
13C核磁気共鳴スペクトル〔(CDCl3 )δC ppm〕は、溶媒としてCDCl3 を、基準物質としてTMS(27℃)を用い、サンプル3%濃度で行ったところ、14.2(q),22.8(t),26.0(t),28.7(t),29.3(t),29.4(t),29.8(t×7),32.0(t),65.3(t),127.6(d),132.1(d),133.2(d),134.2(s),162.3(s)であった。
質量分析〔EIMS(%)〕の結果は、338(M+ ,61),305(5),210(32),129(100),111(66)であった。
赤外線吸収スペクトル〔IRνmax(KBr)cm-1〕の結果は、2920,2850,1710,1520,1470,1270,1100であった。
なお、得られた物質の 1H核磁気共鳴スペクトルのチャートを図6に、13C核磁気共鳴スペクトルのチャートを図7に、質量分析結果のチャートを図8に、赤外線吸収スペクトルのチャートを図9に、ガスクロマトグラフィーのチャートを図10に示す。
【0013】
〈合成例3〉
n−Pentadecyl tetrahydro−2−furoateの合成。
300mlフラスコ中にH管を付け、この中にtetrahydro−2−furoic acid 18.6g(0.16mol)、n−Pentadecanol 30.0g(0.13mol)、トシルアルコール1水和物 1g、及びトルエン200mlを仕込んだ。この溶液を115℃で5時間共沸させ、水分を除去した。なお、この時点での留出水量は約2.3mlであった。
共沸後、この溶液を冷却し、飽和炭酸ナトリウム水溶液200ml内に注入してから、この中からトルエン層を取り出した。
取り出したトルエン層を飽和炭酸ナトリウム水溶液200mlで一回洗い、さらに地下カン水200mlで一回洗った後、トルエンを蒸発させて濃縮して原油48.0gを得、これをさらに蒸留塔にて蒸留した。
蒸留条件及び収量を表2に示す。
【表 2】
表2に記載の通り、n−Pentadecyl tetrahydro−2−furoate(分画2)の収量は38.0gであり、収率は90%であった。得られた物質の同定は 1H核磁気共鳴スペクトル、13C核磁気共鳴スペクトル、質量分析、赤外線吸収スペクトル、ガスクロマトグラフィーによって行った。 1H核磁気共鳴スペクトル〔(CDCl3 )δH ppm〕は、溶媒としてCDCl3 を、基準物質としてTMS(27℃)を用い、サンプル1%濃度で行ったところ、0.88(3H,t,−CH3),1.26(26H,−(CH2)13−),1.60(2H,m,−CH2 −4),1.94(2H,m,−CH2 −3),3.93(2H,m,−CH2−5),4.13(2H,t,−COO−CH2−),4.44(1H,dd,−CH−2)であった。
13C核磁気共鳴スペクトル〔(CDCl3 )δC ppm〕は、溶媒としてCDCl3 を、基準物質としてTMS(27℃)を用い、サンプル3%濃度で行ったところ、14.0(q),22.6(t),25.1(t),25.7(t),28.5(t),29.1(t),29.2(t),29.6(t×7),30.1(t),31.8(t),64.8(t),69.1(t),76.7(d),173.3(s)であった。
質量分析〔EIMS(%)〕の結果は、326(M+ ,2),225(3),210(3),71(100),43(22)であった。
赤外線吸収スペクトル〔IRνmax(KBr)cm-1〕の結果は、2920,2860,1750,1730,1460,1200,1090であった。
なお、得られた物質の 1H核磁気共鳴スペクトルのチャートを図11に、13C核磁気共鳴スペクトルのチャートを図12に、質量分析結果のチャートを図13に、赤外線吸収スペクトルのチャートを図14に、ガスクロマトグラフィーのチャートを図15に示す。
【0014】
上記のように合成された複素単環カルボン酸エステル系新規物質は優れた育毛作用を有するため、これら新規物質を含有する育毛剤は優れた育毛効果を奏する。以下、この発明の実施例及び試験例を記載することにより、この発明の効果を明確にする。
〈実施例1〉n−Pentadecyl−2−furoate 1.25gに5%−1,3−ブチレングリコールのエタノール溶液を加えて全量を25mlとして、実施例1の検体とした。
〈参考例1〉n−Pentadecyl−2−thenoate 1.25gに5%−1,3−ブチレングリコールのエタノール溶液を加えて全量を25mlとして、参考例1の検体とした。
〈参考例2〉n−Pentadecyl tetrahydro−2−furoate 1.25gに5%−1,3−ブチレングリコールのエタノール溶液を加えて全量を25mlとして、参考例2の検体とした。
〈対照例〉5%−1,3−ブチレングリコールのエタノール溶液25mlを対照例の検体とした。
【0015】
〈比較例〉
n−ペンタデシルニコチネート1.25gに5%−1,3−ブチレングリコールのエタノール溶液を加えて全量を25mlとして、比較例の検体とした。
【0016】
上記した実施例1、参考例1乃至2、対照例、比較例の検体を使用し、それぞれ下記の試験を行った。C3H/HeN Crjマウス(8週齢、体重21〜26g)を一週間以上馴化飼育を行ったあと、異常のなかったものについて、背部の被毛を2cmx4cmの範囲を電気バリカンで毛刈りし、さらに電気バリカン(0.05mm刃)で除毛し、検体の投与部位とした。除毛してから3日後、実施例1、参考例1乃至2、対照例及び比較例の検体を各10匹の上記マウスに連続19日間、100μlずつ、1日1回午前中に塗布した。試験期間中、C3H/HeN Crjマウスは、温度22±2℃、相対湿度55±15%、換気回数20回/時、照射時間を6時間から18時間に設定した飼育室で、プラスチック製ゲージ(15x23x15.5)(cm)を用いて1匹ずつ飼育した。育毛効果について、以下のように評価をした。
皮膚がピンク色を呈する−−−(1点)。
皮膚が灰色に変化(出現率30%未満)−−−2点。
皮膚が灰色に変化(出現率30%以上、60%未満)、且つ毛の伸長が認められる(出現率30%未満)−−−3点。
皮膚が灰色に変化(出現率60%以上)、且つ毛の伸長が認められる(出現率30%以上、60%未満)−−−4点。
毛の伸長が認められる(出現率60%以上)−−−5点。
【0017】
実施例1、参考例1乃至2、対照例、及び比較例について、育毛状態の10匹の平均値をスコアとして表3に示す。
【表3】
【0018】
上記の表3に示される通り、この発明の複素単環カルボン酸エステル系新規物質は、公知の育毛成分と比較して、優れた育毛作用を有する。以下、上記複素単環カルボン酸エステル系新規物質を配合した、育毛剤組成物の処方例1を表4に示す。
〈処方例1〉
【表4】
【0019】
【発明の効果】
この発明の新規物質n−Pentadecyl−2−furoateは優れた育毛作用を有し、この化合物が配合された育毛剤組成物は優れた育毛効果を奏する。
【図面の簡単な説明】
【図 1】新規物質n−Pentadecyl−2−furoateの 1H核磁気共鳴スペクトルのチャートである。
【図 2】新規物質n−Pentadecyl−2−furoateの13C核磁気共鳴スペクトルのチャートである。
【図 3】新規物質n−Pentadecyl−2−furoateの質量分析結果のチャートである。
【図 4】新規物質n−Pentadecyl−2−furoateの赤外線吸収スペクトルのチャートである。
【図 5】新規物質n−Pentadecyl−2−furoateのガスクロマトグラフィーのチャートである。
【図 6】新規物質n−Pentadecyl−2−thenoateの 1H核磁気共鳴スペクトルのチャートである。
【図 7】新規物質n−Pentadecyl−2−thenoateの13C核磁気共鳴スペクトルのチャートである。
【図 8】新規物質n−Pentadecyl−2−thenoateの質量分析結果のチャートである。
【図 9】新規物質n−Pentadecyl−2−thenoateの赤外線吸収スペクトルのチャートである。
【図10】新規物質n−Pentadecyl−2−thenoateのガスクロマトグラフィーのチャートである。
【図11】新規物質n−Pentadecyl tetrahydro−2−furoateの 1H核磁気共鳴スペクトルのチャートである。
【図12】新規物質n−Pentadecyl tetrahydro−2−furoateの13C核磁気共鳴スペクトルのチャートである。
【図13】新規物質n−Pentadecyl tetrahydro−2−furoateの質量分析結果のチャートである。
【図14】新規物質n−Pentadecyl tetrahydro−2−furoateの赤外線吸収スペクトルのチャートである。
【図15】新規物質n−Pentadecyl tetrahydro−2−furoateのガスクロマトグラフィーのチャートである。[0001]
BACKGROUND OF THE INVENTION
TECHNICAL FIELD The present invention relates to a novel group of heteromonocyclic carboxylic acid esters and a hair nourishing composition containing these novel substances and similar substances. The purpose of the invention is to provide novel substances having excellent hair-growth action and these novel substances or their analogues. An object of the present invention is to provide a hair-restoring agent composition having an excellent hair-growth effect containing a substance.
The hair-restoring agent composition according to the present invention may belong to any of pharmaceuticals, quasi-drugs, cosmetics and the like under the Pharmaceutical Affairs Law.
[0002]
[Prior art]
Conventionally, as a hair nourishing agent, those described in JP-A-1-250310: the name of the invention “hair growth agent” have been disclosed.
However, the nicotinic acid ester of n-pentadecanol disclosed in JP-A-1-250310 does not have a sufficient hair-restoring action, and a hair nourishing agent containing these as an active ingredient has not been effective enough for practical use.
Therefore, it has been desired to create a compound having a further excellent hair-growth action and a hair-growth composition having an excellent hair-growth effect.
[0003]
[Problems to be solved by the invention]
In view of the above circumstances, an object of the present invention is to provide a novel substance having an excellent hair-growth action and a hair nourishing composition containing these novel substances and exhibiting an excellent hair-growth effect.
[0004]
[Means for Solving the Problems]
The invention described in
[Chemical 2 ]
The invention described in
[0005]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, embodiments of the present invention will be described in detail.
The novel heterocyclic monocyclic carboxylic acid ester substance according to
[Chemical 3 ]
n-Pentadecyl-2-furoate has a molecular weight of 322, a melting point of 36 to 37 ° C., and brown crystals at room temperature.
[0006]
Hereinafter, the method for synthesizing the novel heteromonocyclic carboxylic acid ester-based substance of the present invention will be described. The novel substance of the invention n- pentadecanol (of 4) and heteromonocyclic carboxylic acid 2-furoic acid (of 5), 2-thenoic acid (of 6), tetrahydro-2-furoic acid with (Formula 7) Is synthesized by esterification.
[Formula 4]
[Chemical formula 5]
[Chemical 6]
[Chemical 7]
The method of esterification is not particularly limited as long as it follows a conventional method, but these n-pentadecanol and heteromonocyclic carboxylic acid are dissolved in a solvent capable of dissolving both n-pentadecanol and heteromonocyclic carboxylic acid. Examples of the method include dissolving, adding a catalyst, and heating to a predetermined temperature for condensation.
[0008]
Hereinafter, the synthesis method heteromonocyclic carboxylic acid ester-based compound is a novel substance to be used in the present invention will be described. The heterocyclic monocyclic carboxylic acid ester compound used in the present invention is synthesized by esterifying n-pentadecanol (Chemical Formula 8 ) and a heterocyclic monocyclic carboxylic acid (Chemical Formula 9 ).
[Chemical 8]
[Chemical 9]
For
Embedded image
[0009]
Synthesized by the method described above, since with the hair - growth action novel substance n-Pentadecyl-2-furoat e , when formulated as effective ingredients, a suitable hair tonic is obtained. In this case, the blending amount is preferably about 0.01 to 10%. This is because if the blending amount is less than 0.01%, the hair growth effect may not be obtained, and even if the blending amount exceeds 10%, a significant improvement in hair growth effect cannot be expected. In addition to the above active ingredients, the hair nourishing agent of the present invention may contain a blood circulation promoter, a local stimulant, and the like. Specifically, vitamin E and its derivatives, assembly extract, garlic extract, cephalanthin, carpronium chloride, acetylcholine, etc. Blood circulation promoter, chili tincture, cantalis tincture, ginger tincture, noniric acid vanillamide and other local stimulants, keratolytic agents such as salicylic acid, resorcin, lactic acid, placenta extract, pentadecanoic acid glyceride, pantothenyl ether, biotin, Metabolic activators such as hinokitiol and allantoin, anti-inflammatory agents such as glycyrrhizic acid and glycyrrhetinic acid, bactericides such as isopropylmethylphenol, triclosan, zinc pyrithione and hinokitiol, refreshing agents such as menthol and camphor, and other female hormones Yibin combination can be formulated. Further, in the present invention, in addition to those described above, other ordinary components, that is, alcohol, polyhydric alcohol, water-soluble polymer, antioxidant, pH adjuster, as long as the effects and system of the present invention are not impaired. Ordinary cosmetic ingredients such as UV protection agents, sequestering agents, thickeners, surfactants, purified water, fragrances, preservatives, antibacterial agents, oil agents, higher fatty acids, fatty acid esters, humectants, cooling agents, pigments, Or hormones, vitamins, amino acids, astringents and placenta extract, elastin, collagen, mucopolysaccharide, aloe extract, loofah water, royal jelly, birch, carrot extract, chamomile extract, licorice extract, salvia extract, altea extract, Special blending components such as animal and plant extract components such as herbal medicine components such as Achillea millefolium extract may be optionally blended appropriately.
[0010]
【Example】
Hereinafter, a method for synthesizing a novel heteromonocyclic carboxylic acid ester-based substance of the present invention will be described based on Synthesis Examples 1 to 3 .
[0011]
<Synthesis Example 1>
Synthesis of n-Pentadecyl-2-furoate.
An H tube was attached to a 300 ml flask, and 2-furoic acid 17.9 g (0.16 mol), n-pentadecanol 30.0 g (0.13 mol), tosyl alcohol monohydrate 1 g, and
Thereafter, 2 g of tosyl alcohol monohydrate was added to the solution, and the mixture was further azeotroped for 8 hours to remove moisture. At this time, the total amount of distillate was about 2.3 ml.
After azeotropic distillation, this solution was cooled and poured into 200 ml of a saturated aqueous sodium carbonate solution, and the toluene layer was taken out of the solution.
The taken-out toluene layer was washed once with 200 ml of saturated aqueous sodium carbonate solution and further washed once with 200 ml of subsurface water, and then evaporated to concentrate to obtain 42.0 g of crude oil. This crude oil was recrystallized with 80 ml of 95% ethanol to obtain 36.0 g of brown crystals having a melting point of 36 to 37 ° C. The yield was 86%.
The obtained substance was identified by 1 H nuclear magnetic resonance spectrum, 13 C nuclear magnetic resonance spectrum, mass spectrometry, infrared absorption spectrum, and gas chromatography. 1 H nuclear magnetic resonance spectrum [(CDCl 3 ) δ H ppm] was measured at 0.88 (3H, t) using CDCl 3 as a solvent and TMS (27 ° C.) as a reference substance at a concentration of 1%. , -CH3), 1.26 (24H, - (CH2) 12 -), 1.70 (2H, m, -COO-CH2- CH 2 -), 4.30 (2H, t, -COO-CH2- ), 6.49 (1H, dd, -CH-4), 7.16 (1H, dd, -CH-3), 7.57 (1H, dd, -CH-5).
The 13 C nuclear magnetic resonance spectrum [(CDCl 3 ) δ C ppm] was measured at a concentration of 3% using CDCl 3 as a solvent and TMS (27 ° C.) as a reference substance. 22.8 (t), 26.0 (t), 28.8 (t), 29.3 (t), 29.4 (t), 29.4 (t × 7), 32.0 (t) 65.1 (t), 111.8 (d), 117.7 (d), 145.0 (s), 146.2 (d), and 158.9 (s).
The results of mass spectrometry [EIMS (%)] were 322 (M + , 38), 277 (4), 210 (14), 113 (100), and 95 (42).
The results of the infrared absorption spectrum [IRνmax (KBr) cm −1 ] were 3100, 2920, 2850, 1720, 1705, 1580, 1475, 1300, 1130, 1020, 770.
The 1 H nuclear magnetic resonance spectrum chart of the obtained substance is shown in FIG. 1, the 13 C nuclear magnetic resonance spectrum chart is shown in FIG. 2, the mass analysis result chart is shown in FIG. 3, and the infrared absorption spectrum chart is shown. 4 shows a gas chromatography chart.
[0012]
<Synthesis Example 2>
Synthesis of n-Pentadecyl-2-thenoate.
An H tube was attached to a 300 ml flask, and 20.5 g (0.16 mol) of 2-thenoic acid, 30.0 g (0.13 mol) of n-pentadecanol, 1 g of tosyl alcohol monohydrate, and 200 ml of toluene were charged therein. . This solution was azeotroped at 115 ° C. for 5 hours to remove moisture. At this time, the amount of distilled water was about 1.0 ml.
Thereafter, 2 g of tosyl alcohol monohydrate was added to the solution, and the mixture was further azeotroped for 8 hours to remove moisture. At this time, the total amount of distilled water was about 2.2 ml.
After azeotropic distillation, this solution was cooled and poured into 200 ml of a saturated aqueous sodium carbonate solution, and the toluene layer was taken out of the solution.
The taken-out toluene layer was washed once with 200 ml of saturated aqueous sodium carbonate solution and further washed once with 200 ml of underground water. Then, toluene was evaporated and concentrated to obtain 50.0 g of crude oil, which was further distilled in a distillation column. did.
The distillation conditions and yield are shown in Table 1.
[Table 1]
As shown in Table 1, the yield of n-Pentadecyl-2-thenoate (Fraction 2) was 41.0 g, and the yield was 93%.
The obtained substance was identified by 1 H nuclear magnetic resonance spectrum, 13 C nuclear magnetic resonance spectrum, mass spectrometry, infrared absorption spectrum, and gas chromatography.
1 H nuclear magnetic resonance spectrum [(CDCl 3 ) δ H ppm] was measured at 0.88 (3H, t) using CDCl 3 as a solvent and TMS (27 ° C.) as a reference substance at a concentration of 1%. , -CH3), 1.26 (24H, - (CH2) 12 -), 1.73 (2H, m, -COO-CH2- CH 2 -), 4.28 (2H, t, -COO-CH2- ), 7.07 (1H, dd, -CH-4), 7.52 (1H, dd, -CH-3), 7.78 (1H, dd, -CH-5).
The 13 C nuclear magnetic resonance spectrum [(CDCl 3 ) δ C ppm] was measured at a concentration of 3% using CDCl 3 as a solvent and TMS (27 ° C.) as a reference substance. 22.8 (t), 26.0 (t), 28.7 (t), 29.3 (t), 29.4 (t), 29.8 (t × 7), 32.0 (t) 65.3 (t), 127.6 (d), 132.1 (d), 133.2 (d), 134.2 (s), and 162.3 (s).
The results of mass spectrometry [EIMS (%)] were 338 (M + , 61), 305 (5), 210 (32), 129 (100), and 111 (66).
The results of the infrared absorption spectrum [IRνmax (KBr) cm −1 ] were 2920, 2850, 1710, 1520, 1470, 1270, 1100.
The 1 H nuclear magnetic resonance spectrum chart of the obtained substance is shown in FIG. 6, the 13 C nuclear magnetic resonance spectrum chart is shown in FIG. 7, the mass analysis result chart is shown in FIG. 8, and the infrared absorption spectrum chart is shown. 9 shows a gas chromatography chart in FIG.
[0013]
<Synthesis Example 3>
Synthesis of n-Pentadecyl tetrahydro-2-furoate.
An H tube was attached in a 300 ml flask, and 18.6 g (0.16 mol) of tetrahydro-2-furoic acid, 30.0 g (0.13 mol) of n-pentadecanol, 1 g of tosyl alcohol monohydrate, and 200 ml of toluene Was charged. This solution was azeotroped at 115 ° C. for 5 hours to remove moisture. At this time, the amount of distilled water was about 2.3 ml.
After azeotropic distillation, this solution was cooled and poured into 200 ml of a saturated aqueous sodium carbonate solution, and the toluene layer was taken out of the solution.
The taken-out toluene layer was washed once with 200 ml of saturated aqueous sodium carbonate solution and further washed once with 200 ml of ground water. After that, the toluene was evaporated and concentrated to obtain 48.0 g of crude oil, which was further distilled in a distillation column. did.
The distillation conditions and yield are shown in Table 2.
[Table 2]
As shown in Table 2, the yield of n-Pentadecyl tetrahydro-2-furoate (Fraction 2) was 38.0 g, and the yield was 90%. The obtained substance was identified by 1 H nuclear magnetic resonance spectrum, 13 C nuclear magnetic resonance spectrum, mass spectrometry, infrared absorption spectrum, and gas chromatography. 1 H nuclear magnetic resonance spectrum [(CDCl 3 ) δ H ppm] was measured at 0.88 (3H, t) using CDCl 3 as a solvent and TMS (27 ° C.) as a reference substance at a concentration of 1%. , -CH3), 1.26 (26H, - (CH2) 13 -), 1.60 (2H, m, -CH 2 -4), 1.94 (2H, m, -CH 2 -3), 3 .93 (2H, m, -CH2-5), 4.13 (2H, t, -COO-CH2-), 4.44 (1H, dd, -CH-2).
The 13 C nuclear magnetic resonance spectrum [(CDCl 3 ) δ C ppm] was measured at a sample concentration of 3% using CDCl 3 as a solvent and TMS (27 ° C.) as a reference substance. 22.6 (t), 25.1 (t), 25.7 (t), 28.5 (t), 29.1 (t), 29.2 (t), 29.6 (t × 7) 30.1 (t), 31.8 (t), 64.8 (t), 69.1 (t), 76.7 (d), and 173.3 (s).
The results of mass spectrometry [EIMS (%)] were 326 (M + , 2), 225 (3), 210 (3), 71 (100), and 43 (22).
The results of the infrared absorption spectrum [IRνmax (KBr) cm −1 ] were 2920, 2860, 1750, 1730, 1460, 1200, and 1090.
The 1 H nuclear magnetic resonance spectrum chart of the obtained substance is shown in FIG. 11, the 13 C nuclear magnetic resonance spectrum chart is shown in FIG. 12, the mass analysis result chart is shown in FIG. 13, and the infrared absorption spectrum chart is shown. 14 shows a gas chromatography chart.
[0014]
Since the novel heterocyclic monocyclic carboxylic acid ester-based substance synthesized as described above has an excellent hair-growth action, a hair-restoring agent containing these novel substances has an excellent hair-growth effect. Hereinafter, the effects of the present invention will be clarified by describing examples and test examples of the present invention.
<Example 1> n-Pentadecyl-2-furoate A sample of Example 1 was prepared by adding an ethanol solution of 5% -1,3-butylene glycol to 1.25 g to make a total volume of 25 ml.
The total amount of 25ml was added to <Reference Example 1> n-Pentadecyl-2- thenoate 1.25g to 5% 1,3-butylene glycol ethanol solution was a sample of Reference Example 1.
As <Reference Example 2> n-Pentadecyl tetrahydro-2 -furoate 1.25g of 5% 1,3 added to bring the total amount of the ethanol solution butylene glycol 25 ml, and the sample of Reference Example 2.
<Control Example> 25 ml of ethanol solution of 5% -1,3-butylene glycol was used as a control sample.
[0015]
<Comparative example>
An ethanol solution of 5% -1,3-butylene glycol was added to 1.25 g of n-pentadecyl nicotinate to make a total volume of 25 ml, which was used as a comparative sample.
[0016]
Using the samples of Example 1 , Reference Examples 1 and 2 , Control Example and Comparative Example, the following tests were performed. After C3H / HeN Crj mice (8 weeks old, body weight 21-26 g) had been acclimated for one week or longer, those with no abnormalities were shaved with a hair clipper in the range of 2 cm × 4 cm, The hair was removed with an electric clipper (0.05 mm blade) to provide a specimen administration site. Three days after depilation , the samples of Example 1 , Reference Examples 1 to 2 , Control and Comparative Examples were applied to 10 mice each for 100 days in the morning once a day for 19 consecutive days. During the test period, C3H / HeN Crj mice were kept in plastic cages (22 ± 2 ° C., relative humidity 55 ± 15%,
The skin has a pink color --- (1 point).
Skin turns gray (incidence less than 30%) --- 2 points.
Skin turns gray (
Skin turns gray (appearance rate 60% or more) and hair elongation is observed (
Elongation of hair is observed (appearance rate of 60% or more)-5 points.
[0017]
For Example 1 , Reference Examples 1 and 2 , Control and Comparative Examples, the average value of 10 hair-growing states is shown in Table 3 as a score.
[Table 3]
[0018]
As shown in Table 3 above, the novel heterocyclic monocyclic carboxylic acid ester-based substance of the present invention has an excellent hair-growth action as compared with known hair-growth ingredients. Table 4 shows Formulation Example 1 of the hair restorer composition in which the above-mentioned heteromonocyclic carboxylic acid ester-based novel substance is blended.
<Prescription Example 1>
[Table 4]
[0019]
【The invention's effect】
The new material n-Pentadecyl-2-furoate of the invention has excellent hair growth effect, hair growing agent composition compound of this is compounded exhibits an excellent hair growth effect.
[Brief description of the drawings]
FIG. 1 is a chart of 1 H nuclear magnetic resonance spectrum of a novel substance n-Pentadecyl-2-furoate.
FIG. 2 is a chart of 13 C nuclear magnetic resonance spectrum of a novel substance n-Pentadecyl-2-furoate.
FIG. 3 is a chart of mass analysis results of a novel substance n-Pentadecyl-2-furoate.
FIG. 4 is a chart of an infrared absorption spectrum of a novel substance n-Pentadecyl-2-furoate.
FIG. 5 is a gas chromatography chart of a novel substance n-Pentadecyl-2-furoate.
FIG. 6 is a chart of 1 H nuclear magnetic resonance spectrum of a novel substance n-Pentadecyl-2-thenoate.
FIG. 7 is a chart of 13 C nuclear magnetic resonance spectrum of a novel substance n-Pentadecyl-2-thenoate.
FIG. 8 is a chart of mass analysis results of a novel substance n-Pentadecyl-2-thenoate.
FIG. 9 is a chart of an infrared absorption spectrum of a novel substance n-Pentadecyl-2-thenoate.
FIG. 10 is a gas chromatography chart of a novel substance n-Pentadecyl-2-thenoate.
FIG. 11 is a chart of 1 H nuclear magnetic resonance spectrum of a novel substance n-Pentadecyl tetrahydro-2-furoate.
FIG. 12 is a chart of 13 C nuclear magnetic resonance spectrum of a novel substance n-Pentadecyl tetrahydro-2-furoate.
FIG. 13 is a chart of mass spectrometry results of a novel substance n-Pentadecyl tetrahydro-2-furoate.
FIG. 14 is a chart of an infrared absorption spectrum of a novel substance n-Pentadecyl tetrahydro-2-furoate.
FIG. 15 is a gas chromatography chart of a novel substance n-Pentadecyl tetrahydro-2-furoate.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20244997A JP4170419B2 (en) | 1997-07-10 | 1997-07-10 | Heteromonocyclic carboxylic ester-based novel substance and hair nourishing composition containing novel substance |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20244997A JP4170419B2 (en) | 1997-07-10 | 1997-07-10 | Heteromonocyclic carboxylic ester-based novel substance and hair nourishing composition containing novel substance |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH1129563A JPH1129563A (en) | 1999-02-02 |
JP4170419B2 true JP4170419B2 (en) | 2008-10-22 |
Family
ID=16457718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP20244997A Expired - Fee Related JP4170419B2 (en) | 1997-07-10 | 1997-07-10 | Heteromonocyclic carboxylic ester-based novel substance and hair nourishing composition containing novel substance |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4170419B2 (en) |
-
1997
- 1997-07-10 JP JP20244997A patent/JP4170419B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH1129563A (en) | 1999-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3409165B2 (en) | Hair restorer and its production method | |
JPS60109544A (en) | Novel chalcone derivative and ultraviolet light absorber containing it | |
JP2002535347A (en) | Crude drug preparation containing biotin | |
JP3223404B2 (en) | Hair restorer | |
JPH05306231A (en) | Skin external preparation | |
JP3973748B2 (en) | Hair growth inhibitor | |
JP2000038334A (en) | Whitening cosmetics containing resorcinol derivatives | |
JP2000336017A (en) | Hair tonic raw material and hair tonic composition | |
JP4170419B2 (en) | Heteromonocyclic carboxylic ester-based novel substance and hair nourishing composition containing novel substance | |
JP3195683B2 (en) | Skin cosmetics | |
JPH1160450A (en) | Hair tonic | |
JP2001010926A (en) | Bleaching agent | |
JP2003500431A (en) | How to treat hair loss | |
EP0755671B1 (en) | Dermatologic preparation | |
JP4503788B2 (en) | Hair restorer composition | |
JP3105691B2 (en) | Melanin inhibitor | |
JP2000327551A (en) | Humectant | |
JP2003095859A (en) | Pigmentation inhibitor, method for producing the same and use thereof | |
JP2001172197A (en) | Skin preparation for external use | |
JP3916786B2 (en) | Skin cosmetics | |
KR100769579B1 (en) | Cosmetic composition for improving skin wrinkles | |
JPH0585917A (en) | New hair growing agent composition | |
JP2000505092A (en) | 3-Aryl-2,4-dioxooxazolidine family compounds and their use in cosmetics and pharmaceuticals | |
JP3122534B2 (en) | Hair Restoration / Hair Restoration Composition | |
JP4213837B2 (en) | Hair restorer composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080204 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080207 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080328 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080804 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080807 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110815 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |